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the drugs. Therefore, monitoring and readjustment of the 
dose/s is often necessary to optimize treatment. In the 
present study, two diseases (diabetes and gastric ulcers) that 
may co-exist and require chronic treatment were considered 
and the occurrence of interaction between the concurrently 
used drugs was assessed 
Diabetes mellitus is a disease characterized by elevated 
blood glucose levels. It requires treatment for prolonged 
periods, usually lifelong. Diabetic patients may also have 
other diseases, e.g., peptic ulcers, infectious diseases, etc. 
In such situations, treatment for the different ailments 
will have to be given simultaneously. Peptic ulcer is one 
such disorder that requires treatment for a prolonged 
period. There are several patients who suffer from both 
INTRODUCTION
Drug–drug interactions may occur when more than one 
drug is administered in a patient to treat a single ailment 
or multiple ailments. These concomitantly used drugs 
may either cause pharmacodynamic or pharmacokinetic 
types of interactions. The net result of both the types 
of interactions is the alteration in the therapeutic effect 
of either or both the drugs. There are several diseases 
that require treatment for the lifetime, e.g., diabetes and 
hypertension. Patients with such diseases will often need 
to be administered drugs for treatment of other co-existing 
diseases, either for a short period or lifelong. There is then 
a possibility of occurrence of interactions between drugs, 
resulting in either reduced or enhanced effects of any of 
Clinical Pharmacy
A Study on Drug-Drug Interaction of Esomeprazole and  
Anti-Diabetic Drugs
Swamy VKM, Setty RS1, Shankaraiah MM, Jyothi TM, Rajendra SV
Department of Pharmacology, S.C.S. College of Pharmacy, Harapanahalli - 583 131, Karnataka, India, 
1College of Clinical Pharmacy, King Faisal University, Alahsa - 31982, Kingdom of Saudi Arabia
Address for correspondence: Dr Ramachandra Siddam Setty; E-mail: rssiddamsetty@rediffmail.com
ABSTRACT
Drug–drug interaction between esomeprazole at therapeutic and higher doses and sulfonylureas was studied. 
Sulfonylureas (tolbutamide 40 mg/kg and glibenclamide 40 μg/kg) were administered and the time to onset of 
hypoglycemia, the duration of the hypoglycemia, and the peak hypoglycemia were determined. Esomeprazole 
(1.8 mg/kg, 3.6 mg/kg, and 30 mg/kg) was administered for 8 days and its influence on sulfonylurea-induced 
hypoglycemia was studied. Therapeutic doses of esomeprazole, i.e., 1.8 mg/kg and 3.6 mg/kg dose did not 
influence the hypoglycemia induced by sulfonylureas. However, a higher dose, i.e., 30 mg/kg, did significantly 
enhance the duration of hypoglycemia and the peak hypolgycemia. Esomeprazole (30 mg/kg) by itself did not 
reduce the blood glucose levels; therefore, a pharmacodynamic type of drug interaction can be ruled out. Similarly, 
a pharmacokinetic type of drug interaction may be ruled out at therapeutic doses. The CYP isoenzyme system 
involved in the metabolism of sulfonylureas are not very sensitive to esomeprazole and the dose and frequency 
of administration of sulfonylurea need not be readjusted when they are used concomitantly with esomeprazole 
(at therapeutic doses).
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diabetes and peptic ulcers. In such patients, H2-receptor 
blockers or proton pump inhibitors are administered 
concomitantly with sulfonylureas or insulin preparations. 
There are reports that H2-receptor blockers such as 
ranitidine inhibit the metabolism of sulfonylureas and 
enhance their bioavailability.[1,2] Similarly, there are 
reports that chronic usage of omeprazole increases the 
peak concentration and apparent elimination half-life of 
phenytoin in healthy male volunteers.[3] CZP2C9 is the 
enzyme responsible for the metabolism of phenytoin 
and sulfonylureas. Therefore it is hypothesized that 
esomeprazole may influence the metabolism of study 
drugs. In addition, there is a report that omeprazole 
increased the duration of hypoglycemia and peak 
hypoglycemia induced by sulfonylureas in healthy albino 
rabbits.[4] One report has been published showing that 
proton pump inhibitors like lansoprazole induce the 
cytochrome-P450 enzyme system.[5] Lansoprazole at 
two dose levels – 30 mg/kg and 60 mg/kg for 7 days 
– significantly enhanced the duration of hypoglycemia 
induced by tolbutamide and the peak hypoglycemia 
slightly; the time to onset of hypoglycemia was not 
altered significantly. Similarly, pretreatment with 
lansoprazole has been shown to enhance the peak 
hypoglycemia and the duration of hypoglycemia induced 
by glibenclamide in healthy rabbits.[6] Pretreatment 
with pantoprazole, 10 mg/kg for 7 days, increased 
the peak hypoglycemia and the duration of action of 
glipizide in healthy rabbits and rats as well as in diabetic 
rats.[7] However, there are no such reports regarding 
interactions between esomeprazole and antidiabetic 
agents. Hence, the present study planned to assess the 
interaction between esomeprazole and oral antidiabetic 
agents such as tolbutamide and glibenclamide. 
MATERIALS AND METHODS
The esomeprazole used in this study was from Micro Labs 
Ltd., Bangalore; the tolbutamide from Albert David Ltd., 
Bombay; and the glibenclamide from Aventis Pharma 
Ltd., Goa. 
Animals
Albino rats of either sex, weighing 150–250 g, were 
procured from Sri. Venkateshwara Enterprises, Bangalore, 
and were stored under standard husbandry conditions. 
They were used for the study after a 7-day acclimatisation 
period. Permission for the usage of animals and approval 
of the experimental protocols for the study was obtained 
from the institutional animal ethics committee prior to the 
experimentation. The Registration No. for institutional 
animal house is 157/1999/CPCSEA.
Experimental procedure
Albino rats of either sex (150–250 g), maintained 
under standard conditions, were randomly distributed 
into 6 groups of 6 animals each. The experiment was 
conducted in two phases. In the first phase, after fasting 
for 18 hours all the animals of groups 1, 2, and 3 were 
administered tolbutamide (40 mg/kg) and groups 4, 
5, and 6 were given glibenclamide (40 µg/kg) orally. 
Zero-hour blood samples were collected for estimation 
of fasting blood glucose levels. Blood samples were 
collected at 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 30, 36, 42, 
and 48 hours from the tail vein of all the rats after drug 
treatment. Blood glucose levels were estimated.[8] In the 
second phase, after 1 day of the respective sulfonylurea 
treatment, the animals of groups 1 and 4 received 
esomeprazole 1.8 mg/kg, groups 2 and 5 received 
esomeprazole 3.6 mg/kg, and groups 3 and 6 received 
esomeprazole 30 mg/kg for a period of 8 days. During 
this period the animals had free access to food and water 
supplied ad libitum. On the 7th day, the rats were fasted 
for 18 hours, with water supplied ad libitum. On the 8th 
day, esomeprazole was administered and the zero-hour 
blood sample was collected from all the animals of all 
the groups. The animals of groups 1, 2, and 3 were 
administered tolbutamide (40 mg/kg) and groups 4, 5, 
and 6 were given glibenclamide (40 µg/kg) orally. Blood 
samples were collected at the above-mentioned prefixed 
time intervals and blood glucose levels were estimated. 
Statistical analysis 
The data is presented as mean±standard error of the mean. 
Analysis was by using Student’s ‘t’ test. P≤0.05 is considered 
as statistically significant.
RESULTS
Esomeprazole 30 mg/kg per se did not alter the blood 
glucose levels [Figure 1]. Tolbutamide 40 mg/kg and 
glibenclamide 40 µg/kg induced a peak hypoglycemia 
of 68.47±2.01 mg% and 70.17±2.09 mg%, respectively. 
The time to onset of hypoglycemia (i.e., the time taken 
to achieve at least 20% reduction in blood glucose levels) 
by both the drugs was about 1 hour, and the duration of 
hypoglycemia (i.e., the duration for which at least 20% 
reduction in blood glucose level maintained) was 40 h. 
However, esomeprazole at doses of 1.8 mg/kg and 3.8 
mg/kg did not influence the hypoglycemia induced by 
tolbutamide and glibenclamide. The results are shown Swamy, et al. J Young Pharm. 2010;2(4): 424-427
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in Tables 1 and 2. The pilot studies showed no influence 
of pretreatment with esomeprazole (up to 20 mg/kg) 
on the hypoglycemia induced by oral tolbutamide and 
glibenclamide. Therefore, we tried to assess the influence 
of more than eight times the therapeutic dose of 
esomeprazole (i.e., 30 mg/kg) on hypoglycemia induced 
by sulfonylureas. Tolbutamide- and glibenclamide-induced 
hypoglycemia was enhanced significantly by pretreatment 
with esomeprazole at the dose of 30 mg/kg; Pretreatment 
with esomeprazole enhanced the tolbutamide induced 
peak hypoglycemia from 59.11±3.78 mg% to 64.53±1.05 
mg% and glibenclamide induced peak hypoglycemia 
from 64.97±1.42 mg% to 72.05±4.93, mg% respectively. 
Similarly, the duration of hypoglycemia was also enhanced 
significantly. The results are compiled in.
DISCUSSION
Esomoprazole at 30 mg/kg dose did not by itself reduce 
the blood glucose level, indicating that any interaction 
with antidiabetic drugs in this study is not of the 
pharmacodynamic type. In the present study, therapeutic 
doses of esomeprazole did not influence any of the 
parameters of the hypoglycemia induced by sulfonylureas. 
However, at 8 times the therapeutic dose, esomeprazole 
enhanced the duration of hypoglycemia as well as the 
peak level of hypoglycemia induced by sulfonylureas. The 
literature reports reveal that sulfonylureas are metabolized 
mainly by CYP2C9 and CYP3A.[9] At the dose of 30 mg/kg 
esomeprazole probably inhibits these isoenzymes. Since it 
requires eight times the therapeutic doses of esomeprazole 
to inhibit the CYP isoenzymes that are responsible for 
metabolism of sulfonylureas, these enzymes apparently 
have low sensitivity/affinity for esomeprazole. 
It may be concluded that during concomitant administration 
of sulfonylureas and esomeprazole at therapeutic doses, 
drug–drug interaction does not occur. Therefore, the 
therapeutic dose and the frequency of administration of 
sulfonylureas need not be adjusted. 
Figure 1: Blood glucose level with esomeprazole (30 mg/kg) in healthy 
rat
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Table 1: Percentage blood glucose reduction with tolbutamide in healthy albino rats before and after esomeprazole  
Esomeprazole (1.8 mg/kg) + tolbutamide  
(40 mg/kg)
Esomeprazole (3.6 mg/kg) + tolbutamide  
(40 mg/kg)
Esomeprazole (30 mg/kg) + tolbutamide 
 (40 mg/kg)
Before esomeprazole 
(mean±SEM)
After esomeprazole 
(mean±SEM)
Before esomeprazole 
(mean±SEM)
After esomeprazole 
(mean±SEM)
Before esomeprazole 
(mean±SEM)
After esomeprazole 
(mean±SEM)
Fasting - - - - - -
0.5 28.27±3.70 14.16± 2.79*** 18.43±4.48 21.34±2.43 8.61±3.08 15.55±2.01*
1.0 43.82±3.90 23.57 ± 2.66*** 25.90±4.38 28.58±3.78 24.34±3.78 41.70±2.04**
2.0 50.78±5.43 31.20 ± 2.97*** 33.91±2.61 42.00±3.27* 36.51±2.99 36.79±3.71
4.0 59.02±3.53 42.94 ± 1.52*** 46.89±3.33 54.29±2.10* 48.27±4.15 52.81±1.45
6.0 68.47±2.01 52.45 ± 2.23*** 51.58±1.53 59.12±1.36** 52.47±5.17 56.60±4.54
8.0 56.47 ± 3.44 65.45 ± 1.04** 57.53±3.69 68.02±2.61* 59.11±3.78 61.46±2.36
12.0 39.79 ± 4.62 56.84 ± 3.56** 65.90±1.70 67.22±4.04 47.40±4.05 64.53±1.05**
18.0 33.07 ± 3.93 43.87 ± 3.57* 59.27±4.76 51.17±2.88* 40.18±4.42 53.79±1.33*
24.0 27.30 ± 5.76 33.44 ± 3.92 48.15±5.59 43.92±4.50 36.45±3.21 50.22±2.40**
30.0 24.47 ± 5.82 29.76 ± 3.36 37.99±5.99 34.64±3.09 32.17±4.51 49.08±1.11**
36.0 30.59 ± 9.32 22.10 ± 2.99 29.68±4.52 29.37±4.85 26.37±2.19 42.72±4.86**
42.0 20.44 ± 4.47 17.30 ± 1.91 20.96±2.59 16.66±3.77 19.73±1.18 32.39±3.47**
48.0 13.30 ± 3.32 9.45 ± 2.54 9.28±2.22 10.93 ± 2.39 8.18±3.18 20.63±3.53*
*Significant at P<0.05; **Highly significant at P<0.01; ***Very highly significant at P<0.001Drug interaction of esomeprazole and anti-diabetic drugs
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Table 2: Percentage blood glucose reduction with glibenclamide in healthy albino rats before and after 
esomeprazole  
Esomeprazole (1.8 mg/kg) + glibenclamide 
(40 µg /kg)
Esomeprazole (3.6 mg/kg) + glibenclamide 
(40 µg /kg)
Esomeprazole (30 mg/kg) + glibenclamide 
(40 µg /kg)
Before esomeprazole 
(mean ± SEM) 
After esomeprazole 
(mean ± SEM)
Before esomeprazole 
(mean ± SEM) 
After esomeprazole 
(mean ± SEM) 
Before esomeprazole 
(mean ± SEM) 
After esomeprazole 
(mean ± SEM) 
Fasting - - - - - -
0.5 28.96±3.78 13.58 ± 2.35** 21.75±2.53 17.36± 5.41 16.36±1.72 42.91±1.04***
1.0 44.91±4.02 23.35 ± 2.19*** 29.11 ± 3.90 25.71±4.87 38.80±8.81 64.16±0.85**
2.0 52.05±5.59 31.26 ± 2.66** 42.71 ± 3.30 36.16±2.80 42.43±9.72 70.52±0.52**
4.0 60.49±3.65 43.39 ± 1.39*** 55.20 ± 1.97 47.56±3.55* 57.51±3.00 −
6.0 70.17±2.09 53.32 ± 2.01*** 60.11 ± 1.09 52.69±1.76** 64.97±1.42 72.05±4.93
8.0 58.07±3.55 66.72 ± 1.06* 69.14 ±2.40 58.49±4.41* 58.66±3.21 65.79±1.84*
12.0 40.77±4.72 57.80 ± 3.57** 68.29 ± 3.80 67.25±2.51 58.38±3.93 56.60±3.86
18.0 33.85±4.02 44.39±3.45* 52.06±2.94 60.60±4.59 50.92±2.79 51.86±1.40
24.0 27.98±5.90 33.61±3.62 44.64±4.59 49.29±5.16 45.68±1.16 −
30.0 25.07±5.95 29.77±3.03 35.18±2.99 38.62±5.40 45.05±2.78 68.68±1.44***
36.0 31.33±9.53 21.73±3.05 29.84±4.92 29.97±3.73 38.35±3.65 58.63±2.91***
42.0 20.93±4.57 16.68±2.58 16.87±3.73 20.70±2.46 37.04±1.28 55.02±1.75***
48.0 13.62±3.39 8.54±3.20 11.06±2.35 8.49±2.19 32.34±2.56 46.74±1.20***
*Significant at P<0.05; **Highly significant at P<0.01 ***Very highly significant at P<0.001
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